5J6 Stock Overview Designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
OssDsign AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for OssDsign Historical stock prices Current Share Price SEK 0.85 52 Week High SEK 0.91 52 Week Low SEK 0.47 Beta 0.80 1 Month Change 12.98% 3 Month Change 59.44% 1 Year Change 13.73% 3 Year Change 4.79% 5 Year Change n/a Change since IPO -41.37%
Recent News & Updates
Third quarter 2024 earnings released: kr0.10 loss per share (vs kr0.50 loss in 3Q 2023) Nov 13
Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023) Aug 21
OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member Jun 25
OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024 May 17
First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023) May 15 OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024 See more updates
Third quarter 2024 earnings released: kr0.10 loss per share (vs kr0.50 loss in 3Q 2023) Nov 13
Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023) Aug 21
OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member Jun 25
OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024 May 17
First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023) May 15 OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024
No longer forecast to breakeven Apr 17
OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer Feb 29
Forecast breakeven date moved forward to 2024 Feb 07
Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022) Feb 07
OssDsign AB (publ), Annual General Meeting, May 21, 2024 Feb 06
Forecast breakeven date moved forward to 2024 Jan 25
OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion Jan 24 OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024
OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION Jan 09
Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023 Dec 06
An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD). Dec 02
OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024 Nov 21 OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million. Sep 29
OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023 Sep 27
OssDsign Receives FDA Clearance for A New Major Indication Sep 19
Now 22% undervalued Sep 05
Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022) Aug 23
Forecast breakeven date moved forward to 2024 May 24
Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021) Apr 30
No longer forecast to breakeven Mar 15
Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021) Feb 22 OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023
Forecast to breakeven in 2025 Dec 31 OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million. Dec 01
Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021) Nov 23
Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021) Aug 24
OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity Aug 18
High number of new directors Jul 31
OssDsign AB (publ) Elects Jill Shiaparelli as Board Member Jun 02
First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021) May 25
Insufficient new directors Apr 27
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 24
OssDsign AB (publ), Annual General Meeting, Jun 02, 2022 Feb 22
Insufficient new directors Feb 02
OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst Jan 14
Forecast to breakeven in 2024 Jan 01
OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects Dec 05
Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020) Nov 18
Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020) Aug 21
Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery Jun 03
OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million. May 13
New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants May 05
First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020) Apr 21
Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer Mar 13 OssDsign AB (publ), Annual General Meeting, Jun 04, 2021
New 90-day low: €1.35 Feb 18
Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019) Feb 12
Revenue misses expectations Feb 12
OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures Jan 21
New 90-day low: €1.36 Dec 05
Chairman of the Board recently bought €26k worth of stock Nov 16
Svensson's CFO Claes Lindblad Is Leaving the Company Nov 14
Third quarter 2020 earnings released: kr1.10 loss per share Nov 12
Revenue misses expectations Nov 12
OssDsign AB (publ) to Report Fiscal Year 2020 Results on Feb 17, 2021 Nov 11
New 90-day low: €1.42 Nov 05 OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.169392 million.
Earnings released Aug 20
OssDsign AB (publ) Announces Chief Executive Officer Changes Aug 19 Shareholder Returns 5J6 DE Medical Equipment DE Market 7D 5.2% -0.01% -0.1% 1Y 13.7% -8.8% 7.4%
See full shareholder returns
Return vs Market: 5J6 exceeded the German Market which returned 7.4% over the past year.
Price Volatility Is 5J6's price volatile compared to industry and market? 5J6 volatility 5J6 Average Weekly Movement 16.4% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5J6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5J6's weekly volatility has increased from 10% to 16% over the past year.
About the Company OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. It offers OssDsign Catalyst, a nanosynthetic bone graft used to help stimulate bone growth in spinal fusions. The company was founded in 2011 and is headquartered in Uppsala, Sweden.
Show more OssDsign AB (publ) Fundamentals Summary How do OssDsign's earnings and revenue compare to its market cap? 5J6 fundamental statistics Market cap €89.79m Earnings (TTM ) -€7.90m Revenue (TTM ) €11.14m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5J6 income statement (TTM ) Revenue SEK 127.49m Cost of Revenue SEK 14.48m Gross Profit SEK 113.01m Other Expenses SEK 203.45m Earnings -SEK 90.44m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
Earnings per share (EPS) -0.93 Gross Margin 88.64% Net Profit Margin -70.94% Debt/Equity Ratio 0.2%
How did 5J6 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 14:34 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OssDsign AB (publ) is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Rickard Anderkrans ABG Sundal Collier Sponsored null null ABG Sundal Collier Sponsored Kristofer Liljeberg-Svensson Carnegie Commissioned Research
Show 1 more analysts 
